The trial, sponsored by Qianfoshan Hospital, aims to evaluate the efficacy of CAZ-AVI in combination with ATM against MBL-producing Enterobacterales, a significant concern in antibiotic resistance. The market for antibiotics targeting resistant bacteria is expanding due to rising incidences of multi-drug resistant infections. Successful outcomes could position CAZ-AVI and ATM as a preferred treatment option, potentially leading to increased market share in the antibiotic sector. The incorporation of CRISPR/Cas9 technology may also open avenues for novel therapeutic approaches, enhancing the asset's attractiveness to investors and partners. However, the competitive landscape includes established antibiotics and emerging therapies, necessitating thorough diligence on market positioning and regulatory pathways.